Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Zobair M Younossi , Vlad Ratziu , Rohit Loomba , Mary Rinella , Quentin M Anstee , Zachary Goodman , Pierre Bedossa , Andreas Geier , Susanne Beckebaum , Philip N Newsome , David Sheridan , Muhammad Y Sheikh , James Trotter , Whitfield Knapple , Eric Lawitz , Manal F Abdelmalek , Kris V Kowdley , Aldo J Montano-Loza , Jerome Boursier , Philippe Mathurin , Elisabetta Bugianesi , Giuseppe Mazzella , Antonio Olveira , Helena Cortez-Pinto , Isabel Graupera , David Orr , Lise Lotte Gluud , Jean-Francois Dufour , David Shapiro , Jason Campagna , Luna Zaru , Leigh MacConell , Reshma Shringarpure , Stephen Harrison , Arun J Sanyal The Lancet(2019)
摘要
Intercept Pharmaceuticals.
更多 查看译文
AI 理解论文
溯源树
样例